AI in Life Science Analytics Market Size, Share

Rising R&D and Clinical Trial Complexity Propels Market Growth

Rising R&D and clinical trial complexity is a key market driver for AI in life science analytics as protocols are becoming harder to execute with more endpoints, tighter eligibility, more sites/countries, and heavier operational oversight. Thus, sponsors and CROs need AI to keep timelines and budgets under control. As complexity increases, teams rely on AI analytics to improve trial feasibility, site/country selection, enrollment forecasting, and risk-based monitoring, helping detect underperforming sites early and correct courses faster. This directly raises demand for AI-enabled analytics platforms that can combine operational trial data with external signals and continuously update forecasts. It also pushes companies to standardize analytics stacks across portfolios so they can replicate best practices across studies. Overall, complexity turns AI from an innovation project into an operational necessity for predictable delivery and faster decision-making. Thus, the overall market growth is driven by all these factors cumulatively mentioned above.

• For instance, in June 2025, IQVIA announced it launched new AI agents for life sciences and healthcare, positioned to help the industry enhance, streamline, and focus clinical trials using AI applications trained on healthcare-specific information.

MARKET RESTRAINT

Regulatory, Privacy, and Governance Constraints to Hamper Market Growth

Regulatory, privacy, and governance constraints restrain the market as life-science data is highly-sensitive (trial, patient-level, and safety) and the output is often used to support regulated decisions. As a result, companies must implement strict controls around data provenance, consent/permissions, audit trails, model transparency, and ongoing monitoring for drift, which increases cost and lengthens deployment timelines. Cross-border data rules and data residency expectations can further limit the ability to centralize datasets for model training, forcing fragmented architectures that slow scaling. For GenAI/NLP use cases, governance is even harder as organizations must manage prompt/context controls, hallucination risk, and traceability for generated outputs. These requirements typically push firms from quick pilots to longer validation-heavy programs, delaying ROI and slowing broader rollouts, especially in clinical and safety workflows.  Further, this results in limiting the growth in the market to a certain extent.

• For instance, in January 2025, the U.S. FDA published a Federal Register notice announcing a draft guidance titled “Considerations for the Use of Artificial Intelligence (AI) to Support Regulatory Decision-Making for Drug and Biological Products”, which emphasizes expectations around the AI system’s context of use, data quality, transparency, and risk management—adding compliance workload that can slow adoption of AI-generated evidence in regulated submissions.

MARKET OPPORTUNITIES

Manufacturing & Quality Digitalization to Present Significant Market Growth Opportunities

The digitization of manufacturing and quality presents a significant market opportunity in AI for life science analytics, as biopharma facilities face the challenge of enhancing right-first-time production, minimizing deviations/CAPA cycle time, and boosting throughput without a corresponding increase in capital expenditure. By digitizing batch records, equipment data, and quality events, companies establish a more robust data foundation that enables AI to advance from mere reporting to predictive quality, process enhancement, and earlier identification of drift, which may lead to investigations or batch loss. This creates ongoing demand for AI analytics platforms that integrate MES/QMS/LIMS data, standardize governance, and implement validated models across multi-site networks. The potential is particularly significant since manufacturing programs generally expand across facilities after ROI has been demonstrated, leading to consistent software deployments along with integration and validation services. However, all these above factors would be responsible to drive the growth in the market in the forthcoming years.

• For instance, in November 2025, Teva launched “Rise,” a global open innovation platform explicitly aimed at accelerating AI, Industry 4.0 and smart manufacturing solutions including manufacturing and supply chain challenges.

MARKET CHALLENGES

Lack of Skilled Professionals Pose a Prominent Challenge to Market Growth

The lack of skilled personnel poses a significant market challenge for AI in life science analytics, as expanding beyond pilot projects requires individuals who can integrate domain workflows with AI/ML/GenAI engineering, along with skills in validation and governance. Numerous organizations can purchase software, yet they face difficulties in operationalizing it due to deficiencies in data engineering, model risk management, and expertise for “GxP-ready” implementation. This delays the incorporation into SOPs, raises reliance on costly outside services, and leads to bottlenecks in model oversight, record-keeping, and audit preparedness. The disparity is greater when teams need to manage unstructured data (PV narratives, protocols, batch records) as NLP/GenAI necessitates stringent controls. All the factors cumulatively affect the market growth.

• For instance, according to the BioPharm International survey-based report published in October 2025, nearly half of respondents said their organization’s workforce was unprepared for digital transformation (skills/training/mindset).

Segmentation Analysis

By Component

Advancements in Software Deployments to Boost Segment’s Growth

Based on the component, the market is bifurcated into services and software.

The software segment captured the largest global market share. This is as most buyers prefer scalable, reusable platforms that can be rolled out across multiple functions such as clinical, RWE, safety, manufacturing without rebuilding the same analytics logic every time. Additionally, the growth of the segment is also supported by the launch of new products in the market by the operating players.

• For instance, in October 2025, Oracle launched Oracle Analytics Intelligence for Life Sciences, positioned as a pre-built, continuously updated analytics platform leveraging real-world data sources to accelerate insight generation.

The services segment is anticipated to rise with a CAGR of 14.16% over the forecast period.